Published in Rheumatology (Oxford) on November 01, 1999
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis (2008) 3.45
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis (2005) 2.08
Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J Rheumatol (2001) 1.93
Treatment recommendations for psoriatic arthritis. Ann Rheum Dis (2008) 1.85
Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis (2009) 1.70
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis (2006) 1.59
Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis Rheum (2012) 1.58
A need for greater reporting of socioeconomic status and race in clinical trials. Ann Rheum Dis (2004) 1.52
The utility of immunologic laboratory tests in patients with rheumatic diseases. Arthritis Rheum (2001) 1.51
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis (2010) 1.34
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis (2002) 1.33
Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis (2006) 1.32
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis (2008) 1.31
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum (2007) 1.21
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis (2011) 1.17
Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis (2010) 1.16
Patient perceptions concerning pain management in the treatment of rheumatoid arthritis. J Int Med Res (2010) 1.12
Inhibitors of tumor necrosis factor in rheumatoid arthritis: Will that dog hunt? J Rheumatol (1998) 1.08
A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Ann Rheum Dis (2007) 1.07
Health care utilization in patients with gout. Semin Arthritis Rheum (2010) 1.06
The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis--a systematic review. Clin Exp Rheumatol (2005) 1.04
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001). Ann Rheum Dis (2001) 0.95
Use of methotrexate in patients with psoriatic arthritis. Clin Exp Rheumatol (2010) 0.92
Relative versus absolute goals of therapies for RA: ACR 20 or ACR 50 responses versus target values for "near remission" of DAS or single measures. Clin Exp Rheumatol (2004) 0.91
Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis (2013) 0.91
Evaluating severity and status in rheumatoid arthritis. J Rheumatol (2001) 0.90
Benefit/risk of therapies for rheumatoid arthritis: underestimation of the "side effects" or risks of RA leads to underestimation of the benefit/risk of therapies. Clin Exp Rheumatol (2004) 0.90
Access to disease modifying treatments for rheumatoid arthritis patients. Ann Rheum Dis (1999) 0.89
The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk. Clin Exp Rheumatol (2009) 0.88
OMERACT 7 psoriatic arthritis workshop: synopsis. Ann Rheum Dis (2005) 0.84
Dyslipoproteinaemia in a subset of patients with rheumatoid arthritis. Ann Rheum Dis (1994) 0.81
Anti-TNF therapy for other inflammatory conditions. Clin Exp Rheumatol (2002) 0.80
Folic acid and methotrexate in rheumatoid arthritis. Ann Intern Med (1996) 0.80
Complexities in defining remission in rheumatic diseases. Clin Exp Rheumatol (2006) 0.80
Pharmacoeconomic considerations in the treatment of psoriatic arthritis. Rheumatology (Oxford) (2006) 0.80
Quantitative documentation of benefit/risk of new therapies for rheumatoid arthritis: patient questionnaires as an optimal measure in standard care. Clin Exp Rheumatol (2004) 0.79
Cigarette smoking, TB, and TNF inhibitors. Ann Rheum Dis (2003) 0.77
Optimisation of assessment for rheumatic diseases in clinical trials, observational studies and routine clinical care. Clin Exp Rheumatol (2014) 0.77
Development and initial evaluation of a culturally sensitive cholesterol-lowering diet program for Mexican and African American patients with systemic lupus erythematosus. Arthritis Care Res (2000) 0.77
Physician-assisted suicide. N Engl J Med (1996) 0.75
The pain of death. Hosp Pract (1995) (1998) 0.75
Lipid profiles in patients with rheumatoid arthritis. Ann Rheum Dis (1998) 0.75
Exercise-induced asthma. Ann Intern Med (1990) 0.75
Flare of psoriasis and psoriatic arthritis following treatment with granulocyte colony-stimulating factor. Am J Med (1996) 0.75
Disease measures in evaluating the effect of anti-TNF therapy and predicting clinical outcome. Rheumatology (Oxford) (2004) 0.75
Discussion. Section 2: immunomodulatory intervention. Drugs Today (Barc) (2003) 0.75
Alterations in immune function in rats caused by dietary lipotrope deficiency: effect of age. J Nutr (1982) 0.75
Central nervous system angiopathy associated with cocaine abuse. J Rheumatol (1995) 0.75
Internet-based monitoring of patients with rheumatoid arthritis. Clin Exp Rheumatol (2004) 0.75
Tuberculosis and opportunistic infections: relevance to biologic agents. Clin Exp Rheumatol (2004) 0.75
Case histories-oncology. West J Med (1991) 0.75
We say 'xeno', you say 'zevos'. Nat Med (1995) 0.75
Medicine is becoming just another job. Med Econ (1993) 0.75
HTLV-I. Int J Dermatol (1990) 0.75